Imunon, Inc. is a clinical-stage biotechnology company dedicated to the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. The company's ...
Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer
Est. EPS $-0.55 · Revenue $0.00 · 3 analysts
Est. EPS $-0.48 · Revenue $0.00 · 3 analysts
Est. EPS $-2.36 · Revenue $3.93M · 3 analysts
Est. EPS $-0.61 · Revenue $0.00 · 1 analysts
EPS $-3.68 · Revenue $0.00
| Metric | Latest | YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength. | QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes. |
|---|---|---|---|
| RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three). | $0 | — | — |
| Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day. | $-14.5M | +22.2% | +33.8% |
| Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials. | — | — | — |
| Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on). | — | — | — |
| Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales. | — | — | — |
| Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock. | $-14.2M | +24.9% | -101772.4% |
| FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine. | — | — | — |
| Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe. | 14.3% | -46.8% | +590.1% |
| Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking. | 2.32x | +38.6% | +14.4% |
| Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground. | $12.3M | +26.5% | +86.9% |
| Metric | Annual (A vs E) | Annual Surprise | Quarter (A vs E) | Quarter Surprise |
|---|---|---|---|---|
| EPS Surprise | -6.83 vs -7.13 | +4.2% | -0.54 vs -0.55 | +2.2% |
| Revenue Surprise | $0 vs $10.4M | -100.0% | — | — |
| Date | Executive | Title | Security | Side | Shares | Price |
|---|---|---|---|---|---|---|
| Aug 31, 2026 | Eylward Susan | officer: General Counsel and Corp Sec | Common Stock | D | 2,525 | $1.56 |
| Aug 28, 2026 | Tardugno Michael H | director, officer: Executive Chairman of Board | Common Stock | A | 7,371 | $1.60 |
| Aug 28, 2026 | Lindborg Stacy | director, officer: President and CEO | Common Stock | A | 6,822 | $1.60 |
| Aug 28, 2026 | Faller Douglas Vincent | officer: Chief Medical Officer | Common Stock | A | 3,626 | $1.60 |
| Aug 28, 2026 | Eylward Susan | officer: General Counsel and Corp Sec | Common Stock | A | 2,525 | $1.60 |
Operator: Good morning. I will be your conference operator for today. At this time, I would like to welcome everyone to the IMUNON second quarter 26 Financial Results and Business Update Conference Call. I will now turn the call over to Walter Pinto, Managing Director of Investor Relations at KCSA Strategic Communications for introductions. Please go ahead. Thank you, operator, and good morning. Welcome to the IMUNON Second Quarter 26 Financial Results and Business Update Conference Call. Joining us today are Stacy R. Lindborg, President and Chief Executive Officer Doctor. Douglas V. Faller, chief medical officer and Joshua Blacher, chief financial officer. Michael H. Tardugno, the company's Executive Chairman is also on the line for the Q&A portion of today's call. Before we begin, I would like to remind everyone that our remarks today include forward looking statements. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 2 thousand. Include, but are not limited to, statements regarding the timing and enrollment of the company's clinical trials, potential of the company's therapies to address unmet medical needs, the market potential for its product candidates if approved, and the company's plans and expectations for its development programs. Words such as may, will, expect, plan, anticipate, estimate, and intend, identify these forward looking statements actual results may differ materially from those projected. Additional information on the factors that could cause actual results to differ is detailed in Imunon's filings with the Securities and Exchange Commission, which are available at sec.gov. And on the company's website. Forward looking statements made on the call speak only as of today's date, company undertakes no obligation to update them except as required by law. With that, I would now like to turn the call over to Dr. Stacy R. Lindborg. Stacy, please go ahead. Stacy R. Lindborg: Thank you, Walter, and good morning, everyone. Thank you for joining us today and for your continued support of IMUNON. The second quarter marked another period of focused execution and key validation of both IMNN-001, our lead asset, and our TheraPlas Platform. Across our clinical programs, we continue to demonstrate the strength of our data, which is earning growing recognition within the scientific community while remaining disciplined in our execution. Our North Stacy remains unchanged. Bringing a much needed new treatment option to women with ovarian cancer. A disease that affects approximately 300 thousand women worldwide each year, has a 5 year survival rate of roughly 40% and has seen little meaningful advancement in the standard of care for nearly 3 decades. Before we dive into this quarter's progress, I want to invite our investors and members of the media to join us for our R&D Day on September 23 in New York City. We look forward to providing a deeper look at the science, behind …
| Name | Title | Compensation | Gender | Year Born | Status |
|---|---|---|---|---|---|
Stacy R. Lindborg | President, Chief Executive Officer & Director | USD 925,349 | — | 1971 | Active |
Jeffrey W. Church | Interim Chief Financial Officer | USD 798,171 | Male | 1957 | Active |
Michael H. Tardugno | Executive Chairman | USD 571,225 | Male | 1951 | Active |
Douglas V. Faller | Chief Medical Officer | USD 559,462 | — | 1953 | Active |
Joshua Blacher | Interim CFO, Principal Financial Officer & Principal Accounting Officer | — | Male | 1973 | Active |
Kristin Longobardi | Senior Vice President of Strategic Operations | — | Female | — | Active |
Susan Mary Eylward | General Counsel & Corporate Secretary | — | Female | 1980 | Active |
Leading oncology experts and company management will discuss the Phase 3 OVATION 3 study, supporting science and data, clinical progress, and upcoming milestones
Imunon, Inc. (IMNN) Q2 2026 Earnings Call Transcript
Enrollment momentum exceeding expectations is based on highly promising survival (OS) data and well tolerated safety profile demonstrated in the Company's large, randomized Phase II study, OVATION 2 Strong enrollment demonstrates the confidence of principal investigators from prestigious cancer institutions in the trial design and its potential for a successful outcome Enrollment ahead of plan across all study sites. Additional sites opening on pace with projections LAWRENCEVILLE, N.J.
Translational and clinical data reinforce IMNN-001's potential to unlock IL-12's anti-tumor power in ovarian cancer within a highly safe, proprietary mechanism
Preliminary data reinforces IMNN-001 immunotherapy's potential for success in the rapidly recruiting Phase 3 OVATION 3 clinical trial Lower rate of minimal residual disease (MRD)Higher ctDNA clearance with IMNN-001 vs. controlHighly favorable safety and tolerability profile Study, conducted in partnership with Break Through Cancer, provides new translational data and further support for IMNN-001's unique mechanism of remodeling the tumor immune microenvironment LAWRENCEVILLE, N.
